EMR1 | Jotup

Humanigen to Present at the 2021 LD Micro Invitational XI

Retrieved on:

Thursday, June 3, 2021

Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious diseases, Clinical trials, Branches of biology, Clinical medicine, Medicine, EMR1, Lymphoma, Cancer immunotherapy, Chimeric antigen receptor T cell

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced it will present at the 2021 LD Micro Invitational XI, held virtually from June 8- 10, 2021.

Key Points:

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced it will present at the 2021 LD Micro Invitational XI, held virtually from June 8- 10, 2021.
LD Micro is host to some of the most influential conferences in the small-cap world.
Humanigen has been selected to participate in the first day of the conference, during the Hall of Fame session, which highlights some of the top performers since the LD Micro conference began in 2008.
In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.

GM-CSF Gene-Edited CAR-T Data to be Presented at International Society for Cell & Gene Therapy Annual Meeting 2021

Retrieved on:

Wednesday, May 26, 2021

The modulation of intrinsic pathways is not due to an off-target effect and provides additional mechanistic rationale for the improved anti-tumor activity observed with GM-CSFKO CAR-T.

Key Points:

The modulation of intrinsic pathways is not due to an off-target effect and provides additional mechanistic rationale for the improved anti-tumor activity observed with GM-CSFKO CAR-T.
Humanigens immediate focus is on the development of lenzilumab as a therapy for hospitalized, hypoxic COVID-19 patients.
Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.

Humanigen to Present at Jefferies Healthcare Conference

Retrieved on:

Wednesday, May 19, 2021

Biotechnology, Pharmaceutical, Health, Clinical trials, EMR1, Forward-looking statement

Humanigen\xe2\x80\x99s immediate focus is on the development of lenzilumab as a therapy for hospitalized, hypoxic COVID-19 patients.

Key Points:

Humanigen\xe2\x80\x99s immediate focus is on the development of lenzilumab as a therapy for hospitalized, hypoxic COVID-19 patients.
In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.
For more information, visit www.humanigen.com and follow Humanigen on LinkedIn , Twitter and Facebook .\nAll statements other than statements of historical facts contained in this press release are forward-looking statements.
Forward-looking statements reflect management\'s current knowledge, assumptions, judgment, and expectations regarding future performance or events.

Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Hospitalized COVID-19 Patients

Retrieved on:

Wednesday, May 5, 2021

Oncology, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, EMR1, Forward-looking statement

Humanigen\xe2\x80\x99s immediate focus is on the development of lenzilumab as a therapy for hospitalized hypoxic COVID-19 patients.

Key Points:

Humanigen\xe2\x80\x99s immediate focus is on the development of lenzilumab as a therapy for hospitalized hypoxic COVID-19 patients.
In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.
For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter and Facebook.\nAll statements other than statements of historical facts contained in this press release are forward-looking statements.
Forward-looking statements reflect management\'s current knowledge, assumptions, judgment, and expectations regarding future performance or events.

Humanigen to Host Conference Call to Report Phase 3 Topline Results of LenzilumabTM in Patients Hospitalized With COVID-19

Retrieved on:

Monday, March 29, 2021

Details for the upcoming conference are below:

Key Points:

Details for the upcoming conference are below:
This study was a randomized, double-blind, placebo-controlled, multi-center Phase 3 trial for the treatment and prevention of serious and potentially fatal outcomes in patients who were hospitalized with COVID-19 pneumonia.
The primary endpoint was the difference between lenzilumab treatment and placebo treatment in ventilator-free survival through 28 days following treatment.
Humanigens immediate focus is to prevent or minimize cytokine release syndrome that precedes severe lung dysfunction in hospitalized and hypoxic patients with COVID-19 pneumonia.
In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.

Humanigen to Present at Roth Conference

Retrieved on:

Friday, March 5, 2021

Professional services, Health, Infectious diseases, Finance, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Cell biology, Cytokines, Granulocyte-macrophage colony-stimulating factor, EMR1, Macrophage colony-stimulating factor, Coronavirus disease

Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.

Key Points:

Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.
For more information, visit www.humanigen.com and follow Humanigen on LinkedIn , Twitter and Facebook .

Humanigen Expands its anti-GM-CSF Patent Portfolio

Retrieved on:

Tuesday, March 2, 2021

Oncology, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Cytokines, Granulocyte-macrophage colony-stimulating factor, EMR1, Colony-stimulating factor, Macrophage colony-stimulating factor, Macrophage

These two patents expand Humanigens patent portfolio and demonstrate the value of the companys pioneering approach to neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF).

Key Points:

These two patents expand Humanigens patent portfolio and demonstrate the value of the companys pioneering approach to neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF).
Together, these patents continue to solidify Humanigens robust intellectual property portfolio which includes over 100 issued patents and over 50 patent applications.
Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.
In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.

Humanigen to Present at Multiple Investor Conferences in March

Retrieved on:

Thursday, February 25, 2021

Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, Branches of biology, Clinical medicine, Immunology, Cytokines, Granulocyte-macrophage colony-stimulating factor, Cytokine release syndrome, Coronavirus disease, Macrophage colony-stimulating factor, EMR1, Cytokine, Acute respiratory distress syndrome

Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.

Key Points:

Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
Humanigens immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection.
Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.

Humanigen to Present and Participate at Multiple Upcoming Investor and Industry Conferences

Retrieved on:

Thursday, February 11, 2021

Oncology, Health, Infectious diseases, General Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Cytokines, Cell biology, EMR1, Granulocyte-macrophage colony-stimulating factor, Macrophage colony-stimulating factor

Management will also participate in a Fireside Chat with Cantor Fitzgerald Analyst Louise Chen on February 26, 2021.

Key Points:

Management will also participate in a Fireside Chat with Cantor Fitzgerald Analyst Louise Chen on February 26, 2021.
Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.

Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans

Retrieved on:

Monday, November 23, 2020

Infectious diseases, Health, Oncology, Clinical trials, Clinical medicine, Branches of biology, Medicine, Immune system, EMR1, Hypomethylating agent, Leukemia, Lenzilumab, Chimeric antigen receptor T cell

(NASDAQ: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced the establishment of Humanigen Australia Proprietary Limited (Humanigen Australia Pty Ltd), through which Humanigen intends to assess potential partnering opportunities, facilitate clinical development programs, and conduct other corporate and business development activities in the Asia-Pacific region.

Key Points:

(NASDAQ: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced the establishment of Humanigen Australia Proprietary Limited (Humanigen Australia Pty Ltd), through which Humanigen intends to assess potential partnering opportunities, facilitate clinical development programs, and conduct other corporate and business development activities in the Asia-Pacific region.
The study is supported by a grant from the Australian Government's Medical Research Future Fund.
In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.